These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7249281)

  • 61. Veno-venous allografts: patency, subendothelial proliferation, and the role of platelet-active agents.
    Gaudiani VA; Miller DC; Kosek JC; Burg J; Jamieson SW
    J Surg Res; 1983 Mar; 34(3):263-70. PubMed ID: 6834811
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Changes in coagulation and platelet function during prolonged extracorporeal circulation (ECC) in sheep and man.
    Fong SW; Burns NE; Williams G; Woldanski C; Gazzaniga AB; Bartlett RH
    Trans Am Soc Artif Intern Organs; 1974; 20A():239-47. PubMed ID: 4450343
    [No Abstract]   [Full Text] [Related]  

  • 63. The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action.
    Pedersen AK; FitzGerald GA
    Circulation; 1985 Dec; 72(6):1164-76. PubMed ID: 3905047
    [No Abstract]   [Full Text] [Related]  

  • 64. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension.
    Benigni A; Gregorini G; Frusca T; Chiabrando C; Ballerini S; Valcamonico A; Orisio S; Piccinelli A; Pinciroli V; Fanelli R
    N Engl J Med; 1989 Aug; 321(6):357-62. PubMed ID: 2664523
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Thin layer chromatographic identification of thromboxane B2 in serum, and platelet rich plasma stimulated by arachidonic acid and collagen.
    Morris RH; Davies GG
    Ann Clin Biochem; 1993 Mar; 30 ( Pt 2)():203-4. PubMed ID: 8466155
    [No Abstract]   [Full Text] [Related]  

  • 66. Aspirin and other platelet-aggregation inhibiting drugs.
    Gallus AS
    Med J Aust; 1985 Jan; 142(1):41-7. PubMed ID: 3880861
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hematologic responses to prolonged extracorporeal circulation (ECC) with microporous membrane devices.
    Bartlett RH; Fong SW; Woldanski C; Hung E; Styler D; MacArthur C
    Trans Am Soc Artif Intern Organs; 1975; 21():250-7. PubMed ID: 1145997
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of antiplatelet agents on pulmonary haemodynamic response to fMLP in endotoxin primed rats.
    Song C; Suzuki S; Kubo H; Chida M; Hoshikawa Y; Tabata T; Kondo T
    Thorax; 2004 Jan; 59(1):39-44. PubMed ID: 14694246
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase.
    Pedersen AK; FitzGerald GA
    N Engl J Med; 1984 Nov; 311(19):1206-11. PubMed ID: 6436696
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin.
    Gerrard JM; Taback S; Singhroy S; Docherty JC; Kostolansky I; McNicol A; Kobrinsky NL; McKenzie JK; Rowe R
    Circulation; 1989 Jan; 79(1):29-38. PubMed ID: 2910545
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Use of a thromboxane synthetase inhibitor for the protection of platelet number and function during extracorporeal circulation. Experimental study].
    Massonnet Castel S; Pelissier E; Fabiani JN; Terrier E
    Agressologie; 1983 Dec; 24(12):605-8. PubMed ID: 6686919
    [No Abstract]   [Full Text] [Related]  

  • 72. The puzzle of blood platelets in extracorporeal circulation. Comments based on recirculation experiments.
    Wandall HH; Sivertsen U
    Scand J Thorac Cardiovasc Surg; 1975; 9(2):140-3. PubMed ID: 1179195
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Platelet adhesiveness.
    Swedenborg J; Schwartz SI
    J Surg Res; 1975 Aug; 19(2):133-48. PubMed ID: 1152458
    [No Abstract]   [Full Text] [Related]  

  • 74. Thromboxane formation during blood clotting is decreased by verapamil.
    Dahl ML; Uotila P
    Prostaglandins Leukot Med; 1984 Feb; 13(2):217-8. PubMed ID: 6585842
    [No Abstract]   [Full Text] [Related]  

  • 75. Interruption of tumor-associated platelet consumption with platelet enzyme inhibitors.
    Slichter SJ; Weiden PL; O'Donnell MR; Storb R
    Blood; 1982 Jun; 59(6):1252-8. PubMed ID: 6805531
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mechanisms of action of sulphinpyrazone.
    Wallis RB
    Thromb Res Suppl; 1983; 4():31-8. PubMed ID: 6415857
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of sulphinpyrazone and aspirin on platelet adhesion to subendothelium following oral administration to rabbits.
    Davies JA; Menys VC
    Thromb Res; 1981 Feb 15-Mar 1; 21(4-5):329-37. PubMed ID: 7268688
    [No Abstract]   [Full Text] [Related]  

  • 78. Evidence that platelet buoyant density, but not size, correlates with platelet age in man.
    Mezzano D; Hwang K; Catalano P; Aster RH
    Am J Hematol; 1981; 11(1):61-76. PubMed ID: 7270546
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Thromboxane synthesis and platelet protein release during simulated extracorporeal circulation.
    Addonizio VP; Smith JB; Guiod LR; Strauss JF; Colman RW; Edmunds LH
    Blood; 1979 Aug; 54(2):371-6. PubMed ID: 454844
    [No Abstract]   [Full Text] [Related]  

  • 80. Effect of sulfinpyrazone on platelet survival time in patients with transient cerebral ischemic attacks.
    Steele P; Carroll J; Overfield D; Genton E
    Stroke; 1977; 8(3):396-8. PubMed ID: 871029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.